1887

Abstract

Although approximately 3 % of the world's population is infected with (HCV), there is no prophylactic vaccine available. This study reports the design, cloning and purification of a single polyprotein comprising the HCV core protein and non-structural proteins NS3, NS4a, NS4b, NS5a and NS5b. The immunogenicity of this polyprotein, which was formulated in alum, oil-in-water emulsion MF59 or poly(-lactide co-glycolide) in the presence or absence of CpG adjuvant, was then determined in a murine model for induction of B- and T-cell responses. The addition of adjuvants or a delivery system to the HCV polyprotein enhanced serum antibody and T-cell proliferative responses, as well as IFN- responses, by CD4 T cells. The antibody responses were mainly against the NS3 and NS5 components of the polyprotein and relatively poor responses were elicited against NS4 and the core components. IFN- responses, however, were induced against all of the individual components of the polyprotein. These data suggest that the HCV polyprotein delivered with adjuvants induces broad B- and T-cell responses and could be a vaccine candidate against HCV.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81849-0
2006-08-01
2019-11-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/8/2253.html?itemId=/content/journal/jgv/10.1099/vir.0.81849-0&mimeType=html&fmt=ahah

References

  1. Alter, M. J. ( 1993; ). The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 2, 155–166.
    [Google Scholar]
  2. Armstrong, G. L., Alter, M. J., McQuillan, G. M. & Margolis, H. S. ( 2000; ). The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31, 777–782.[CrossRef]
    [Google Scholar]
  3. Bird, A. P. ( 1987; ). CpG islands as gene markers in the vertebrate nucleus. Trends Genet 3, 342–347.[CrossRef]
    [Google Scholar]
  4. Cataldo, D. M. & Van Nest, G. ( 1997; ). The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15, 1710–1715.[CrossRef]
    [Google Scholar]
  5. Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. ( 1989; ). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362.[CrossRef]
    [Google Scholar]
  6. Choo, Q.-L., Richman, K. H., Han, J. H. & 11 other authors ( 1991; ). Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 88, 2451–2455.[CrossRef]
    [Google Scholar]
  7. Choo, Q. L., Kuo, G., Ralston, R. & 15 other authors ( 1994; ). Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91, 1294–1298.[CrossRef]
    [Google Scholar]
  8. Coates, S., Choo, Q. L., Kuo, G. & 16 other authors ( 2004; ). Protection of chimpanzees against heterologous 1a viral challenge using a gpE1/gpE2 heterodimer vaccine. In Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease. Edited by A. R. Jilbert, E. V. L. Grgacic, K. Vickery, C. Burrell & Y. E. Cossart. Melbourne: Australian Centre for Hepatitis Virology.
  9. Cohen, J. ( 1999; ). The scientific challenge of hepatitis C. Science 285, 26–30.[CrossRef]
    [Google Scholar]
  10. Cooper, S., Erickson, A. L., Adams, E. J., Kansopon, J., Weiner, A. J., Chien, D. Y., Houghton, M., Parham, P. & Walker, C. M. ( 1999; ). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439–449.[CrossRef]
    [Google Scholar]
  11. Diepolder, H. M., Zachoval, R., Hoffmann, R. M., Wierenga, E. A., Santantonio, T., Jung, M. C., Eichenlaub, D. & Pape, G. R. ( 1995; ). Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346, 1006–1007.[CrossRef]
    [Google Scholar]
  12. Eyles, J. E., Carpenter, Z. C., Alpar, H. O. & Williamson, E. D. ( 2003; ). Immunological aspects of polymer microsphere vaccine delivery systems. J Drug Target 11, 509–514.[CrossRef]
    [Google Scholar]
  13. Ferrari, G., Humphrey, W., McElrath, M. J., Excler, J.-L., Duliege, A.-M., Clements, M. L., Corey, L. C., Bolognesi, D. P. & Weinhold, K. J. ( 1997; ). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94, 1396–1401.[CrossRef]
    [Google Scholar]
  14. Gerlach, J. T., Diepolder, H. M., Jung, M.-C. & 7 other authors ( 1999; ). Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 117, 933–941.[CrossRef]
    [Google Scholar]
  15. Goh, P.-Y., Tan, Y.-J., Lim, S. P., Lim, S. G., Tan, Y. H. & Hong, W. J. ( 2001; ). The hepatitis C virus core protein interacts with NS5A and activates its caspase-mediated proteolytic cleavage. Virology 290, 224–236.[CrossRef]
    [Google Scholar]
  16. Grakoui, A., Shoukry, N. H., Woollard, D. J., Han, J.-H., Hanson, H. L., Ghrayeb, J., Murthy, K. K., Rice, C. M. & Walker, C. M. ( 2003; ). HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659–662.[CrossRef]
    [Google Scholar]
  17. Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., van Nest, G. A. & Hsu, H. H. ( 1999; ). A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17, 2769–2778.[CrossRef]
    [Google Scholar]
  18. Hemmi, H., Takeuchi, O., Kawai, T. & 9 other authors ( 2000; ). A toll-like receptor recognizes bacterial DNA. Nature 408, 740–745.[CrossRef]
    [Google Scholar]
  19. Higgins, D. A., Carlson, J. R. & Van Nest, G. ( 1996; ). MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14, 478–484.[CrossRef]
    [Google Scholar]
  20. Kanke, M., Sniecinski, I. & DeLuca, P. P. ( 1983; ). Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parenter Sci Technol 37, 210–217.
    [Google Scholar]
  21. Kazzaz, J., Neidleman, J., Singh, M., Ott, G. & O'Hagan, D. T. ( 2000; ). Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 67, 347–356.[CrossRef]
    [Google Scholar]
  22. Klinman, D. M., Currie, D., Gursel, I. & Verthelyi, D. ( 2004; ). Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199, 201–216.[CrossRef]
    [Google Scholar]
  23. Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A. & Klinman, D. M. ( 1995; ). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549.[CrossRef]
    [Google Scholar]
  24. Lechner, F., Wong, D. K. H., Dunbar, P. R. & 7 other authors ( 2000; ). Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191, 1499–1512.[CrossRef]
    [Google Scholar]
  25. Lin, S., Arcangel, P., Medina-Selby, A. & 9 other authors ( 2005; ). Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies. J Clin Microbiol 43, 3917–3924.[CrossRef]
    [Google Scholar]
  26. Lindblad, E. B. ( 2004; ). Aluminium compounds for use in vaccines. Immunol Cell Biol 82, 497–505.[CrossRef]
    [Google Scholar]
  27. Liu, Z.-X., Nishida, H., He, J.-W., Lai, M. M. C., Feng, N. & Dennert, G. ( 2002; ). Hepatitis C virus genotype 1b core protein does not exert immunomodulatory effects on virus-induced cellular immunity. J Virol 76, 990–997.[CrossRef]
    [Google Scholar]
  28. Major, M. E., Mihalik, K., Puig, M., Rehermann, B., Nascimbeni, M., Rice, C. M. & Feinstone, S. M. ( 2002; ). Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76, 6586–6595.[CrossRef]
    [Google Scholar]
  29. McHutchison, J. G., Gordon, S. C., Schiff, E. R. & 7 other authors ( 1998; ). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339, 1485–1492.[CrossRef]
    [Google Scholar]
  30. Missale, G., Bertoni, R., Lamonaca, V. & 7 other authors ( 1996; ). Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98, 706–714.[CrossRef]
    [Google Scholar]
  31. Murphy, J. E., Uno, T., Hamer, J. D., Cohen, F. E., Dwarki, V. & Zuckermann, R. N. ( 1998; ). A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. Proc Natl Acad Sci U S A 95, 1517–1522.[CrossRef]
    [Google Scholar]
  32. Nelson, D. R., Marousis, C. G., Davis, G. L., Rice, C. M., Wong, J., Houghton, M. & Lau, J. Y. ( 1997; ). The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158, 1473–1481.
    [Google Scholar]
  33. O'Hagan, D. T. & Singh, M. ( 2003; ). Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2, 269–283.[CrossRef]
    [Google Scholar]
  34. O'Hagan, D. T., Ott, G. S. & van Nest, G. ( 1997; ). Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 3, 69–75.[CrossRef]
    [Google Scholar]
  35. O'Hagan, D. T., Singh, M., Kazzaz, J., Ugozzoli, M., Briones, M., Donnelly, J. & Ott, G. ( 2002; ). Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20, 3389–3398.[CrossRef]
    [Google Scholar]
  36. O'Hagan, D. T., Singh, M., Dong, C. & 10 other authors ( 2004; ). Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23, 672–680.[CrossRef]
    [Google Scholar]
  37. Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P. & van Nest, G. ( 1995; ). MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In Vaccine Design: the Subunit and Adjuvant Approach, pp. 277–296. Edited by M. F. Powell & M. J. Newman. New York: Plenum.
  38. Otten, G. R., Schaefer, M., Greer, C. & 12 other authors ( 2003; ). Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol 77, 6087–6092.[CrossRef]
    [Google Scholar]
  39. Podda, A. & Del Giudice, G. ( 2003; ). MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2, 197–203.[CrossRef]
    [Google Scholar]
  40. Poynard, T., Marcellin, P., Lee, S. S. & 8 other authors ( 1998; ). Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426–1432.[CrossRef]
    [Google Scholar]
  41. Pulendran, B. ( 2004; ). Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199, 227–250.[CrossRef]
    [Google Scholar]
  42. Ray, R. B., Meyer, K., Steele, R., Shrivastava, A., Aggarwal, B. B. & Ray, R. ( 1998; ). Inhibition of tumor necrosis factor (TNF-α)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 273, 2256–2259.[CrossRef]
    [Google Scholar]
  43. Raz, E. & Spiegelberg, H. L. ( 1999; ). Deviation of the allergic IgE to an IgG response by gene immunotherapy. Int Rev Immunol 18, 271–289.[CrossRef]
    [Google Scholar]
  44. Schetter, C. & Vollmer, J. ( 2004; ). Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9. Curr Opin Drug Discov Devel 7, 204–210.
    [Google Scholar]
  45. Selby, M. J., Choo, Q. L., Berger, K. & 7 other authors ( 1993; ). Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol 74, 1103–1113.[CrossRef]
    [Google Scholar]
  46. Singh, M., Ott, G., Kazzaz, J., Ugozzoli, M., Briones, M., Donnelly, J. & O'Hagan, D. T. ( 2001; ). Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res 18, 1476–1479.[CrossRef]
    [Google Scholar]
  47. Singh, M., Kazzaz, J., Chesko, J., Soenawan, E., Ugozzoli, M., Giuliani, M., Pizza, M., Rappuoli, R. & O'Hagan, D. T. ( 2004a; ). Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 93, 273–282.[CrossRef]
    [Google Scholar]
  48. Singh, M., Kazzaz, J., Ugozzoli, M., Chesko, J. & O'Hagan, D. T. ( 2004b; ). Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin Biol Ther 4, 483–491.[CrossRef]
    [Google Scholar]
  49. Sparwasser, T., Koch, E.-S., Vabulas, R. M., Heeg, K., Lipford, G. B., Ellwart, J. W. & Wagner, H. ( 1998; ). Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28, 2045–2054.[CrossRef]
    [Google Scholar]
  50. Tabata, Y. & Ikada, Y. ( 1988; ). Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 22, 837–858.[CrossRef]
    [Google Scholar]
  51. Tabata, Y. & Ikada, Y. ( 1990; ). Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci 94, 107–141.
    [Google Scholar]
  52. Traquina, P., Morandi, M., Contorni, M. & van Nest, G. ( 1996; ). MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 174, 1168–1175.[CrossRef]
    [Google Scholar]
  53. Tsai, S.-L., Liaw, Y.-F., Chen, M.-H., Huang, C.-Y. & Kuo, G. C. ( 1997; ). Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25, 449–458.[CrossRef]
    [Google Scholar]
  54. Valensi, J. P., Carlson, J. R. & van Nest, G. A. ( 1994; ). Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 153, 4029–4039.
    [Google Scholar]
  55. Xavier, R. M., Nakamura, M. & Tsunematsu, T. ( 1994; ). Isolation and characterization of a human nonspecific suppressor factor from ascitic fluid of systemic lupus erythematosus. Evidence for a human counterpart of the monoclonal nonspecific suppressor factor and relationship to the T cell receptor alpha-chain. J Immunol 152, 2624–2632.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81849-0
Loading
/content/journal/jgv/10.1099/vir.0.81849-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error